Presidency
Paolo A. Ascierto, Director of Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, National Cancer Institute IRCCS Fondazione “G. Pascale”, Naples, Italy
Bernard A. Fox, Chief of Molecular and Tumor Immunology Laboratory, Robert W. Franz Cancer Center Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US
James L. Gulley, Co-Director of the Center for Immuno-Oncology, Center for Cancer Research (CCR), the National Cancer Institute (NCI), Bethesda, MD, US; President of Society for Immunotherapy of Cancer (SITC)
Igor Puzanov, Judith and Sanford Lipsey Chair in Clinical Cancer Research; Senior Vice President, Clinical Investigation Chief, Division of Melanoma, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US
Rational
The Immunotherapy Bridge will start with a Session jointly organized with SITC on modulator of .
Hence, we will discuss the state of the art of immunotherapy, the novel cancer biology and its effects on immune cells, the novel drugs beyond checkpoints and T-cells and then the organ specific immune response to share what different cancers teach about the general understanding of malignancies.
The final session will be focused on neoadjuvant therapies across cancers.
Immunotherapy Bridge will end with the Great Debate Sessions, in which the most important issues from clinical practice and research will be shown and exhaustively discussed from two different points of view.
For any information, please send an email to eventi@vivenko.net or info@melanomabridge.org
Organizing Secretariat
Information
- November 30th - December 1st, 2026
- Naples
- CME Course